How Low Cholesterol Is Good for Anti-viral Immunity
York et al. identify a role for decreased cholesterol biosynthesis in virally infected cells as a critical event in the induction of the anti-viral response. The mechanism involves enhanced signaling by STING in the ER membrane in response to the second messenger cGAMP, promoting increased transcription of type I interferons. The authors suggest that a ''lipid code'' is being sensed by STING to allow it to signal.
Metabolic reprogramming (meaning a reconfiguring of metabolic pathways) occurs in immune cells during challenge with pathogens, their products, or the cytokines that they elicit (Ganeshan and Chawla, 2014; Kelly and O'Neill, 2015) . We still have an incomplete understanding of why these changes occur. Lipid metabolism has been a particular focus, with, for example, the Gram-negative bacterial product LPS signaling via TLR4 downregulating cholesterol biosynthesis, as anti-viral type I interferons do (IFNs) (Blanc et al., 2013) . Paradoxically, type I IFNs have also been shown to promote cholesterol uptake in the face of this decreased biosynthesis (Boshuizen et al., 2015) . In this issue of Cell, York et al. (2015) address this apparently neutral change in cholesterol levels head on and demonstrate that type I IFN signaling indeed shifts the balance away from biosynthesis to uptake of cholesterol. Strikingly, however, they demonstrate that the decrease in cholesterol biosynthesis promotes anti-viral gene expression by the key anti-viral signaling protein STING. STING appears to require a cholesterol-deficient endoplasmic reticulum (ER) membrane from which to signal for type I IFN production. These findings therefore identify a clear molecular consequence for decreased cholesterol synthesis in anti-viral immunity.
The authors begin their study by measuring total and synthesized cholesterol levels in macrophages treated with IFN b, Poly:IC, or LPS or infected with murine gammaherpesvirus-68 (MHV-68). All of these decreased synthesis of cholesterol while increasing the total cholesterol levels in cells. The uptake of cholesterol (contained in LDL particles) was enhanced. Infection with MHV-68 decreased the expression of genes encoding enzymes in the cholesterol biosynthetic pathway and increased expression of genes encoding lipid importers. The effect of MHV-68 was IFN dependent, indicating that it is the induced type I IFN that reprograms cholesterol metabolism in cells, decreasing synthesis and yet promoting uptake.
An obvious question is whether this shift might be important in host defense against viruses. To test this, York and colleagues used mice deficient in key proteins involved in cholesterol biosynthesis. SCAP is a protein required for SREBP2 function, a transcription factor essential for the expression of genes encoding for enzymes in cholesterol biosynthesis (Horton et al., 2002) . Remarkably, SCAP-deficient macrophages had a much lower burden of MHV-68. SREBP2-deficient macrophages were also resistant to MHV-68 and also to Influenza A and HIV-1 challenges. Knockdown of SCAP in THP1 cells rendered them resistant to HIV-1, while SCAP-deficient mice had a much lower MHV-68 viral load in their lungs. Deletion of SCAP can therefore protect against viral infections. Further analysis reveals that SCAP-deficient macrophages spontaneously produced type I IFNs, explaining the anti-viral response in vitro and in vivo. In addition, the induction of type I IFNs was greatly enhanced in response to LPS and Poly:IC in SCAP-deficient macrophages. The authors also tested fibroblasts from humans with a deficiency in mevalonate kinase. The resulting disease is characterized by recurrent fevers and hyper IgD production and is termed Hyper IgD syndrome (HIDS) (Esposito et al., 2014) . Mevalonate kinase is a key enzyme in cholesterol biosynthesis, and indeed the deficient fibroblasts had spontaneously upregulated IFN b production and had a heightened response to poly:IC, providing a possible mechanism for the inflammatory symptoms in HIDS. Overall, these data indicate that viral infection drives type I IFN production (via, for example, TLR3), with the IFN then decreasing cholesterol synthesis. The cell is therefore somehow able to sense this decrease, promoting further type I IFN production and thereby driving the anti-viral response.
The question that then arises is as to what the molecular mechanism might be for type I IFN production when cholesterol biosynthesis is decreased in response to virus. A major pathway to type I IFN production in response to viruses involves sensing of viral DNA by the enzyme cGAS, which generates cGAMP. This second messenger binds to STING, which in turn activates the kinase TBK-1, which phosphorylates and activates IRF3 (Xiao and Fitzgerald, 2013) . cGAS, STING, TBK-1, and IRF3 were all implicated in the enhanced production of type I IFN in the SREBP2-deficient cells. Replenishing cholesterol in SCAP-deficient macrophages reduced TBK-1 phosphorylation, indicating that cholesterol levels directly influence STING signaling both basally and in response to added cGAMP. Therefore, we have a model whereby in order for viruses to induce type I IFN, cholesterol synthesis has to be decreased in order for cGAMP/STING to activate TBK-1. A logical conclusion is that, for STING to signal from the ER, the ER membrane in which STING resides must be cholesterol deficient.
This is an intriguing observation that contributes to our understanding of the role of metabolic reprogramming (and, more specifically, reprogramming of cholesterol metabolism) in anti-viral immunity and prompts a series of interesting questions. First, a sequence of events following viral infection is not fully clear. Do anti-viral TLRs (which do not signal via STING) initiate the process by inducing type I IFN production, which then decreases cholesterol biosynthesis, allowing for enhanced STING activation from cGAS/cGAMP, as depicted in Figure 1 ? Or do these TLRs also decrease cholesterol biosynthesis in order to induce type I IFNs, such that cholesterol levels govern both STING-dependent and STING-independent type I IFN production? Second, precisely how type I IFNs decrease cholesterol biosynthesis, other than by repression of expression of the enzymes involved, is not yet elucidated. Does this involve a decrease in SCAP and/or SREBP2, and if so, how would this decrease occur? Third, how does cholesterol content actually influence STING? Is low cholesterol needed to allow STING to interact with TBK-1? Finally, and perhaps most interestingly, might certain viruses manipulate this pathway by increasing cholesterol biosynthesis to limit STING?
As the authors point out in the discussion of their findings, an important implication from this study is that the cell is able to distinguish newly synthesized cholesterol from the chemically identical imported cholesterol. STING is somehow able to detect cholesterol levels in the ER membrane, such that the level must be low for STING to signal to TBK-1. Given that fatty acid synthesis is also decreased in the response to virus, it is possible that this is also being detected, leading the authors to conclude that a ''lipid code'' is being detected during innate immunity, which is read out as a signal. This code will also be altered when lipid synthesis is enhanced, as occurs, for example, in response to LPS. More work on this lipid code in innate immune signaling could provide important new insights into the precise role of lipid metabolic reprogramming in innate immunity. Probing this frontier further could well give rise to new approaches to boost host defense against pathogens.
ders (Peterson and Toborek, 2014) to name a few. This begs the question: does neuroinflammation contribute to the cognitive impairments that arise in these conditions? A growing body of evidence suggests that this may in fact be the case. One pro-inflammatory cytokine, tumor necrosis factor alpha (TNFa), is elevated in MS and other neuroinflammatory neurological conditions (McCoy and Tansey, 2008) and has been implicated in cognitive alterations (Yirmiya and Goshen, 2011) . But until now, there has been no demonstration of a mechanism by which this cytokine could affect cognition. In this issue of Cell, Habbas et al. (2015) demonstrate that TNFa signals through astrocytes to alter synaptic strength in the hippocampal formation and contribute to contextual memory deficits observed in a rodent model of MS. Habbas et al. (2015) investigate the electrophysiological effects of TNFa on the entorhinal cortex-dentate gyrus (EC-DG) synapse in a slice preparation of mouse hippocampal formation, the brain structure responsible for memory formation and spatial navigation. They find that temporary application of TNFa at pathological levels-but not at lower levels-induces a sustained increase in the frequency of presynaptic vesicular release from entorhinal cortical axons, measured as an increase in the frequency of miniature excitatory postsynaptic currents (mEPSCs) in dentate gyrus granule cells. How might this synaptic alteration be occurring? The same group previously demonstrated that high levels of extracellular TNFa can trigger release of the conventional neurotransmitter glutamate from astrocytes (Santello et al., 2011) and that astrocytic glutamate acts on presynaptic NMDA glutamate receptors to increase the frequency of presynaptic vesicular release (Jourdain et al., 2007) .
